Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines

A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression.

Automated summary

SARS-CoV-2, similar to SARS-CoV, uses its spike protein to bind ACE2 receptor for entry, leading to COVID-19 pandemic. Vaccines encoding for SARS-CoV-2 spike protein are being used to boost antibodies inhibiting viral entry.